Both sides have signed this (Bill Ranking)
H.R. 5160 · 119th Congress (2025-2026)
22 members · Left 9 · Center 6 · Right 7 (Bill Ranking)
| Sponsor | Rep. Smith, Christopher H. (R-NJ) (Introduced 09/04/2025) |
|---|---|
| Sponsor Voting Record | Center · DW-NOMINATE +0.18 · measured from every roll-call vote this member has cast (voteview.com) (Sponsor Ranking) |
| Support |
LLLCLRR support across the spectrum: 22 members signed on (Bill Ranking) this bill: sponsor + current cosponsors, each once |
| Committees | House - Energy and Commerce Committee; House - Energy and Commerce Committee; House - Energy and Commerce Committee |
| Latest Action | 07/21/2026 Received in the Senate. Read twice. Placed on Senate Legislative Calendar under General Orders. Calendar No. 464. |
| Roll Call Votes | There have been no roll call votes |
| Source | view on congress.gov → |
Reported to House (07/02/2026)
Stem Cell Therapeutic and Research Reauthorization Act of 2025
This bill reauthorizes through FY2031 and revises programs that help patients receive transplants of bone marrow or umbilical cord blood from biologically unrelated donors. These programs are administered by the Health Resources and Services Administration (HRSA).
The bill reauthorizes the C.W. Bill Young Cell Transplantation Program. This program supports transplantation of bone marrow and cord blood by increasing the quantities of donations, providing processes for matching and distributing donated materials to patients, and providing related information and research.
Also, the bill reauthorizes and revises the National Cord Blood Inventory program, through which HRSA contracts with qualified cord blood banks to collect and maintain a supply of high-quality units for transplantation through the C.W. Bill Young Cell Transplantation Program. The bill amends the inventory program by (1) changing the inventory goal from 150,000 units to a sufficient supply as determined by HRSA, (2) requiring HRSA to manage the size and composition of the inventory to maximize clinical utility and efficiency, and (3) defining high quality cord blood unit to mean a unit meeting current industry standards and the requirements of the Food and Drug Administration.
119 HR 5160 EH: Stem Cell Therapeutic and Research Reauthorization Act of 2025 U.S. House of Representatives text/xml EN Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain. IB 119th CONGRESS2d Session H. R. 5160
IN THE HOUSE OF REPRESENTATIVES AN ACT To reauthorize the Stem Cell Therapeutic and Research Act of 2005, and for other purposes.
1.Short titleThis Act may be cited as the Stem Cell Therapeutic and Research Reauthorization Act of 2025.
2.Reauthorization of the C.W. Bill Young Cell Transplantation ProgramSection 379B of the Public Health Service Act (42 U.S.C. 274m) is amended— (1)by striking appropriated $31,009,000 and inserting the following: appropriated— (1)$31,009,000; (2)in paragraph (1), as so inserted, by striking the period at the end and inserting ; and; and (3)by adding at the end the following: (2)$33,009,000 for each of fiscal years 2027 through 2031..
3.Cord blood inventory (a)In generalSection 2(a) of the Stem Cell Therapeutic and Research Act of 2005 (42 U.S.C. 274k note) is amended by striking at least 150,000 new units of high-quality cord blood and inserting a sufficient supply, as determined by the Secretary, of high-quality cord blood units. (b)ApplicationSection 2(c) of such Act (42 U.S.C. 274k note) is amended— (1)in paragraph (2), by striking in perpetuity or; and (2)by amending paragraph (5) to read as follows: (5)if the Secretary determines through an assessment, or through petition by the applicant, that a cord blood bank is no longer operational, does not meet the requirements described in subsection (d)(4), or does not meet the requirements of section 379(d)(4) of the Public Health Service Act, and as a result may not distribute the high-quality units, the Secretary may transfer the units collected pursuant to this section to another qualified cord blood bank or entity approved by the Secretary to ensure continued availability of high-quality cord blood units.. (c)Duration of ContractsSection 2(d)(4) of such Act (42 U.S.C. 274k note) is amended to read as follows: (4)Consideration of best scienceThe Secretary shall take into consideration current scientific and clinical information in order to maximize the availability of high-quality cord blood units meeting applicable clinical and quality standards for transplant when entering into contracts under this section, or when extending a period of funding under such a contract under paragraph (2).. (d)Inventory managementSection 2 of such Act (42 U.S.C. 274k note) is amended— (1)by redesignating subsections (e), (f), and (g) and as subsections (f), (g), and (h), respectively; and (2)by inserting after subsection (d) the following: (e)Inventory management (1)In generalThe Secretary shall manage the size and composition of the National Cord Blood Inventory to maximize clinical utility, ensure genetic diversity, and promote the efficient use of resources. (2)ConsiderationsIn carrying out paragraph (1), the Secretary may— (A)on the Secretary’s own initiative or upon petition by a qualified cord blood bank, make determinations regarding the continued storage of cord blood units based on the best available scientific and clinical evidence; or (B)prioritize the collection, retention, or disposition of cord blood units based on scientific, clinical, or operational considerations that the Secretary determines to be relevant.. (e)DefinitionsSection 2(g) of such Act, as redesignated by subsection (d)(1) of this section, is amended— (1)by redesignating paragraphs (4) and (5) as paragraphs (5) and (6), respectively; and (2)by inserting after paragraph (3) the following: (4)The term high quality cord blood unit means a cord blood unit that meets current industry standards and any requirements of the Food and Drug Administration.. (f)Authorization of appropriationsSection 2(h) of such Act, as redesignated by subsection (d)(1) of this section, is amended by striking fiscal years 2022 through 2026 and inserting fiscal years 2027 through 2031. Passed the House of Representatives July 20, 2026.Kevin F. McCumber,Clerk.
119 HR 5160 IH: Stem Cell Therapeutic and Research Reauthorization Act of 2025 U.S. House of Representatives 2025-09-04 text/xml EN Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain. I119th CONGRESS1st SessionH. R. 5160IN THE HOUSE OF REPRESENTATIVESSeptember 4, 2025Mr. Smith of New Jersey (for himself, Ms. Matsui, Mr. Bilirakis, Ms. Pingree, Ms. Tenney, and Mr. Mfume) introduced the following bill; which was referred to the Committee on Energy and CommerceA BILLTo reauthorize the Stem Cell Therapeutic and Research Act of 2005, and for other purposes.
1.Short titleThis Act may be cited as the Stem Cell Therapeutic and Research Reauthorization Act of 2025.
2.Reauthorization of the C.W. Bill Young Cell Transplantation ProgramSection 379B of the Public Health Service Act (42 U.S.C. 274m) is amended— (1)by striking appropriated $31,009,000 and inserting the following: appropriated— (1)$31,009,000; (2)in paragraph (1), as so inserted, by striking the period at the end and inserting ; and; and (3)by adding at the end the following: (2)$33,009,000 for each of fiscal years 2027 through 2031..
3.Cord blood inventorySection 2(g) of the Stem Cell Therapeutic and Research Act of 2005 (42 U.S.C. 274k note) is amended by striking 2026 and inserting 2031.
119 HR 5160 PCS: Stem Cell Therapeutic and Research Reauthorization Act of 2025 U.S. House of Representatives 2026-07-21 text/xml EN Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain. IICalendar No. 464119th CONGRESS2d SessionH. R. 5160IN THE SENATE OF THE UNITED STATESJuly 21, 2026Received; read twice and placed on the calendarAN ACTTo reauthorize the Stem Cell Therapeutic and Research Act of 2005, and for other purposes.1.Short titleThis Act may be cited as the Stem Cell Therapeutic and Research Reauthorization Act of 2025.2.Reauthorization of the C.W. Bill Young Cell Transplantation ProgramSection 379B of the Public Health Service Act (42 U.S.C. 274m) is amended—(1)by striking appropriated $31,009,000 and inserting the following:appropriated—(1)$31,009,000;(2)in paragraph (1), as so inserted, by striking the period at the end and inserting ; and; and(3)by adding at the end the following:(2)$33,009,000 for each of fiscal years 2027 through 2031..3.Cord blood inventory(a)In generalSection 2(a) of the Stem Cell Therapeutic and Research Act of 2005 (42 U.S.C. 274k note) is amended by striking at least 150,000 new units of high-quality cord blood and inserting a sufficient supply, as determined by the Secretary, of high-quality cord blood units. (b)ApplicationSection 2(c) of such Act (42 U.S.C. 274k note) is amended—(1)in paragraph (2), by striking in perpetuity or; and(2)by amending paragraph (5) to read as follows:(5)if the Secretary determines through an assessment, or through petition by the applicant, that a cord blood bank is no longer operational, does not meet the requirements described in subsection (d)(4), or does not meet the requirements of section 379(d)(4) of the Public Health Service Act, and as a result may not distribute the high-quality units, the Secretary may transfer the units collected pursuant to this section to another qualified cord blood bank or entity approved by the Secretary to ensure continued availability of high-quality cord blood units..(c)Duration of ContractsSection 2(d)(4) of such Act (42 U.S.C. 274k note) is amended to read as follows:(4)Consideration of best scienceThe Secretary shall take into consideration current scientific and clinical information in order to maximize the availability of high-quality cord blood units meeting applicable clinical and quality standards for transplant when entering into contracts under this section, or when extending a period of funding under such a contract under paragraph (2)..(d)Inventory managementSection 2 of such Act (42 U.S.C. 274k note) is amended—(1)by redesignating subsections (e), (f), and (g) and as subsections (f), (g), and (h), respectively; and(2)by inserting after subsection (d) the following:(e)Inventory management(1)In generalThe Secretary shall manage the size and composition of the National Cord Blood Inventory to maximize clinical utility, ensure genetic diversity, and promote the efficient use of resources.(2)ConsiderationsIn carrying out paragraph (1), the Secretary may—(A)on the Secretary’s own initiative or upon petition by a qualified cord blood bank, make determinations regarding the continued storage of cord blood units based on the best available scientific and clinical evidence; or(B)prioritize the collection, retention, or disposition of cord blood units based on scientific, clinical, or operational considerations that the Secretary determines to be relevant..(e)DefinitionsSection 2(g) of such Act, as redesignated by subsection (d)(1) of this section, is amended—(1)by redesignating paragraphs (4) and (5) as paragraphs (5) and (6), respectively; and(2)by inserting after paragraph (3) the following:(4)The term high quality cord blood unit means a cord blood unit that meets current industry standards and any requirements of the Food and Drug Administration..(f)Authorization of appropriationsSection 2(h) of such Act, as redesignated by subsection (d)(1) of this section, is amended by striking fiscal years 2022 through 2026 and inserting fiscal years 2027 through 2031.Passed the House of Representatives July 20, 2026.Kevin F. McCumber,Clerk.July 21, 2026Received; read twice and placed on the calendar
119 HR 5160 RH: Stem Cell Therapeutic and Research Reauthorization Act of 2025 U.S. House of Representatives 2026-07-02 text/xml EN Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain. IBUnion Calendar No. 629119th CONGRESS2d SessionH. R. 5160[Report No. 119–724]IN THE HOUSE OF REPRESENTATIVESSeptember 4, 2025Mr. Smith of New Jersey (for himself, Ms. Matsui, Mr. Bilirakis, Ms. Pingree, Ms. Tenney, and Mr. Mfume) introduced the following bill; which was referred to the Committee on Energy and CommerceJuly 2, 2026Additional sponsors: Mrs. Fischbach, Mrs. Dingell, Mr. Gottheimer, Mr. Aderholt, Ms. Malliotakis, Ms. Castor of Florida, Mr. Garbarino, Ms. Norton, Mr. Bentz, Ms. Barragán, Mr. Finstad, Ms. Morrison, Mr. Lawler, Mr. Vindman, Mr. Fitzpatrick, and Ms. Davids of KansasJuly 2, 2026Reported with an amendment, committed to the Committee of the Whole House on the State of the Union, and ordered to be printedStrike out all after the enacting clause and insert the part printed in italicFor text of introduced bill, see copy of bill as introduced on September 4, 2025A BILLTo reauthorize the Stem Cell Therapeutic and Research Act of 2005, and for other purposes.1.Short titleThis Act may be cited as the Stem Cell Therapeutic and Research Reauthorization Act of 2025.2.Reauthorization of the C.W. Bill Young Cell Transplantation ProgramSection 379B of the Public Health Service Act (42 U.S.C. 274m) is amended—(1)by striking appropriated $31,009,000 and inserting the following:appropriated—(1)$31,009,000;(2)in paragraph (1), as so inserted, by striking the period at the end and inserting ; and; and(3)by adding at the end the following:(2)$33,009,000 for each of fiscal years 2027 through 2031..3.Cord blood inventory(a)In generalSection 2(a) of the Stem Cell Therapeutic and Research Act of 2005 (42 U.S.C. 274k note) is amended by striking at least 150,000 new units of high-quality cord blood and inserting a sufficient supply, as determined by the Secretary, of high-quality cord blood units. (b)ApplicationSection 2(c) of such Act (42 U.S.C. 274k note) is amended—(1)in paragraph (2), by striking in perpetuity or; and(2)by amending paragraph (5) to read as follows:(5)if the Secretary determines through an assessment, or through petition by the applicant, that a cord blood bank is no longer operational, does not meet the requirements described in subsection (d)(4), or does not meet the requirements of section 379(d)(4) of the Public Health Service Act, and as a result may not distribute the high-quality units, the Secretary may transfer the units collected pursuant to this section to another qualified cord blood bank or entity approved by the Secretary to ensure continued availability of high-quality cord blood units..(c)Duration of ContractsSection 2(d)(4) of such Act (42 U.S.C. 274k note) is amended to read as follows:(4)Consideration of best scienceThe Secretary shall take into consideration current scientific and clinical information in order to maximize the availability of high-quality cord blood units meeting applicable clinical and quality standards for transplant when entering into contracts under this section, or when extending a period of funding under such a contract under paragraph (2)..(d)Inventory managementSection 2 of such Act (42 U.S.C. 274k note) is amended—(1)by redesignating subsections (e), (f), and (g) and as subsections (f), (g), and (h), respectively; and(2)by inserting after subsection (d) the following:(e)Inventory management(1)In generalThe Secretary shall manage the size and composition of the National Cord Blood Inventory to maximize clinical utility, ensure genetic diversity, and promote the efficient use of resources.(2)ConsiderationsIn carrying out paragraph (1), the Secretary may—(A)on the Secretary’s own initiative or upon petition by a qualified cord blood bank, make determinations regarding the continued storage of cord blood units based on the best available scientific and clinical evidence; or(B)prioritize the collection, retention, or disposition of cord blood units based on scientific, clinical, or operational considerations that the Secretary determines to be relevant..(e)DefinitionsSection 2(g) of such Act, as redesignated by subsection (d)(1) of this section, is amended—(1)by redesignating paragraphs (4) and (5) as paragraphs (5) and (6), respectively; and(2)by inserting after paragraph (3) the following:(4)The term high quality cord blood unit means a cord blood unit that meets current industry standards and any requirements of the Food and Drug Administration..(f)Authorization of appropriationsSection 2(h) of such Act, as redesignated by subsection (d)(1) of this section, is amended by striking fiscal years 2022 through 2026 and inserting fiscal years 2027 through 2031.July 2, 2026Reported with an amendment, committed to the Committee of the Whole House on the State of the Union, and ordered to be printed
The bill's own words, from our database (synced from the GPO BILLS XML); paragraph breaks added at the bill's section boundaries, nothing else changed.
| Date | Chamber | All Actions |
|---|---|---|
| 09/04/2025 | Library of Congress | Introduced in House |
| 09/04/2025 | Library of Congress | Introduced in House |
| 09/04/2025 | House floor actions | Referred to the House Committee on Energy and Commerce. |
| 09/04/2025 | House committee actions | Referred to the Subcommittee on Health. |
| 05/13/2026 | House committee actions | Subcommittee Consideration and Mark-up Session Held |
| 05/13/2026 | House committee actions | Forwarded by Subcommittee to Full Committee by Voice Vote. |
| 05/21/2026 | House committee actions | Committee Consideration and Mark-up Session Held |
| 05/21/2026 | House committee actions | Ordered to be Reported (Amended) by the Yeas and Nays: 48 - 0. |
| 07/02/2026 | Library of Congress | Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 119-724. |
| 07/02/2026 | House floor actions | Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 119-724. |
| 07/02/2026 | House floor actions | Placed on the Union Calendar, Calendar No. 629. |
| 07/20/2026 | House floor actions | Mr. Guthrie moved to suspend the rules and pass the bill, as amended. |
| 07/20/2026 | House floor actions | Considered under suspension of the rules. (consideration: CR H4642-4643) |
| 07/20/2026 | House floor actions | DEBATE - The House proceeded with forty minutes of debate on H.R. 5160. |
| 07/20/2026 | Library of Congress | Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H4642) |
| 07/20/2026 | House floor actions | On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H4642) |
| 07/20/2026 | House floor actions | Motion to reconsider laid on the table Agreed to without objection. |
| 07/21/2026 | Senate | Received in the Senate. Read twice. Placed on Senate Legislative Calendar under General Orders. Calendar No. 464. |
| Title Type | Title |
|---|---|
| Short Title(s) from PCS (Placed on Senate Calendar) bill text | Stem Cell Therapeutic and Research Reauthorization Act of 2025 |
| Short Title(s) as Passed House | Stem Cell Therapeutic and Research Reauthorization Act of 2025 |
| Official Titles from EH (Engrossed in House) bill text | To reauthorize the Stem Cell Therapeutic and Research Act of 2005, and for other purposes. |
| Display Title | Stem Cell Therapeutic and Research Reauthorization Act of 2025 |
| Short Title(s) as Reported to House | Stem Cell Therapeutic and Research Reauthorization Act of 2025 |
| Short Title(s) as Introduced | Stem Cell Therapeutic and Research Reauthorization Act of 2025 |
| Official Title as Introduced | To reauthorize the Stem Cell Therapeutic and Research Act of 2005, and for other purposes. |
There are no amendments to this bill.
* = Original cosponsor
| Committee | Activity |
|---|---|
| House - Energy and Commerce Committee | 07/02/2026 Reported By |
| House - Energy and Commerce Committee | 05/21/2026 Markup By |
| House - Energy and Commerce Committee | 09/04/2025 Referred To |
Policy Area: Health
All data on this page comes from our own database (legislation.congress_* tables), synced daily from the GPO govinfo BILLSTATUS and BILLS collections. Formatted after congress.gov; nothing is generated. Member placement is their DW-NOMINATE score (voteview.com, Lewis et al.) - a measurement of roll-call voting behavior, not our judgement. Buckets: Left below −0.50 · Lean Left to −0.25 · Center to +0.25 · Lean Right to +0.50 · Right above +0.50. The bill's Support meter aggregates the people who signed the bill - sponsor and current cosponsors, each counted once - nothing else.